Stockscreener 앱 받기
3.90
1.02%
-0.04
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris (KLRS): Posts a 0.73% Gain to $4.15 on the Day; Range Check: the Price Remains Bounded by the Supplied Support and Resistance on the DayIV Rank - vinanet.vn
Amy O'leary Vandekop Net Worth (2026) - GuruFocus
Liisa Ann Bayko Net Worth (2026) - GuruFocus
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) Share Price, KLRS Stock News, KLRS Share Price & Updates - Kalkine
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Spurs 4.38% Share AdvanceEarnings Manipulation Risk - vinanet.vn
Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program - VisionMonday.com
Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary - TradingView
Kalaris Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kalaris Therapeutics Q2 Results: EPS beats estimate, losses narrow 21% YoY - scanx.trade
Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Kalaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results - MarketBeat
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kalaris Therapeutics Reports Q2 2026 Results and Advances Phase 1b/2 TH103 Study for Neovascular AMD - Quiver Quantitative
Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on Hand - TradingView
KLRS: TH103 clinical progress and strong cash position support operations into Q4 2027 - TradingView
Kalaris Reports $11.5 Million Q2 Net Loss and TH103 Updates - Quiver Quantitative
BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million - TradingView
Kalaris Therapeutics (KLRS) Slides 2.9% to $4.07 as Biotech Sellers Test Key SupportWeak Sell Signals - vinanet.vn
Kalaris Therapeutics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4%Here's What Happened - MarketBeat
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf - GlobeNewswire
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders - WBOC TV
KLRS Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesTangible Book Value - vinanet.vn
Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsValue Stock Ideas - dars.gov.et
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentMargin Compression Risk - vinanet.vn
Kalaris Therapeutics (KLRS) Sees Modest Gain as Stock Holds Above SupportSign of Weakness - dars.gov.et
Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kalaris Therapeutics Inc (KLRS) Cash Flow - TradingKey
Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Bottom Line Despite No RevenueNet Profit Margin - vinanet.vn
TradingKey - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:3.730|Chg%:-0.190 - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:4.120|Chg%:-0.050 - TradingKey
Kalaris Therapeutics Inc (KLRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kalaris Therapeutics (KLRS) Drops 3.7% as Stock Tests Key Support ZonePoint of Control - vinanet.vn
Kalaris appoints Liisa Bayko as CFO - MSN
Why is Kalaris Therapeutics stock gaining Friday? - MSN
Kalaris Therapeutics Appoints Liisa Bayko as New Chief Financial Officer - VisionMonday.com
Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko - Bitget
Kalaris Therapeutics appoints Liisa Bayko as CFO By Investing.com - Investing.com Nigeria
Kalaris Therapeutics appoints Liisa Bayko as CFO - Investing.com
Kalaris Therapeutics stock falls despite naming new CFO By Investing.com - Investing.com South Africa
Kalaris Therapeutics Appoints Liisa Bayko as New CFO - Contract Pharma
Kalaris Therapeutics stock falls despite naming new CFO - Investing.com
Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026 - marketscreener.com
Kalaris Therapeutics Strengthens Financial Leadership With New CFO - TipRanks
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer - The Manila Times
After more than two decades in biotech finance, Liisa Bayko joins Kalaris - Stock Titan
Kalaris Therapeutics appoints Liisa Bayko as Chief Financial Officer - scanx.trade
Kalaris Therapeutics Slides Nearly 5% as Support Levels Come into FocusFear Greed Extreme - dars.gov.et
Enterprise value to revenue forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
KLRS Dips After Intraday Spike Draws Trader Interest - timothysykes.com
0.86%
0.31%
자본화:
|
볼륨(24시간):